Details of the Drug

General Information of Drug (ID: DME3ZYC)

Drug Name
ALKS 4230
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Drug Type
Protein
Cross-matching ID
TTD ID
DQGF20

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 2 receptor (IL2R) TTAJU0S NOUNIPROTAC Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04592653) A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment (ARTISTRY-3). U.S. National Institutes of Health.
2 ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.